Kyung-Bo Kim, Ph.D.
Dr. Kim’s research lies at the interface between chemistry and biology. Specifically, the Kim lab focuses on the development and biological/pharmacological characterization of small molecule inhibitors targeting the proteasome-ubiquitin pathway.
- Choi EY, Lee H, Dingle RW, Kim KB, Swanson HI. Development of novel CH223191-based antagonists of the aryl hydrocarbon receptor. Mol Pharmacol. 2012 Jan;81(1):3-11. PMID: 21967751
- Wehenkel M, Ban JO, Ho YK, Carmony KC, Hong JT, Kim KB. A selective inhibitor of the immunoproteasome subunit LMP2 induces apoptosis in PC-3 cells and suppresses tumor growth in nude mice. Br J Cancer. 2012 Jun 26;107(1):53-62. PMID: 22677907
- Atkinson SP, Collin J, Irina N, Anyfantis G, Kyung BK, Lako M, Armstrong L. A putative role for the immunoproteasome in the maintenance of pluripotency in human embryonic stem cells. Stem Cells. 2012 Jul;30(7):1373-84. PMID: 22532526
- Jang ER, Lee NR, Han S, Wu Y, Sharma LK, Carmony KC, Marks J, Lee DM, Ban JO, Wehenkel M, Hong JT, Kim KB, Lee W. Revisiting the role of the immunoproteasome in the activation of the canonical NF-κB pathway. Mol Biosyst. 2012 Sep;8(9):2295-302. PMID: 22722901
- Sun H, Lee CM, Tripathi S, Kim KB, Morgan ET. Nitric oxide-dependent CYP2B degradation is potentiated by a cytokine-regulated pathway and utilizes the immunoproteasome subunit LMP2. Biochem J. 2012 Aug 1;445(3):377-82. PMID: 22612225
- Sharma LK, Lee NR, Jang ER, Lei B, Zhan CG, Lee W, Kim KB. Activity-based near-infrared fluorescent probe for LMP7: a chemical proteomics tool for the immunoproteasome in living cells. Chembiochem. 2012 Sep 3;13(13):1899-903. (highlighted on the front cover of ChemBioChem) PMID: 22807337
- Kim KB, Crews CM. From epoxomicin to carfilzomib: chemistry, biology, and medical outcomes. Nat Prod Rep. 2013 May;30(5):600-4. PMID: 23575525
- Carmony KC, Kim KB. Activity-based imaging probes of the proteasome. Cell Biochem Biophys. 2013 Sep;67(1):91-101. PMID: 23700161
- Miller Z, Ao L, Kim KB, Lee W. Inhibitors of the immunoproteasome: current status and future directions. Curr Pharm Des. 2013;19(22):4140-51. PMID: 23181576
- Park JE, Ao L, Miller Z, Kim K, Wu Y, Jang ER, Lee EY, Kim KB, Lee W. PSMB9 codon 60 polymorphisms have no impact on the activity of the immunoproteasome catalytic subunit β1i expressed in multiple types of solid cancer. PLoS One. 2013 Sep 9;8(9):e73732.